Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2021.0307


Genome and transcriptome – based drug discovery and clinical predictors for meaningful  cancer treatment.

Chatterjee S, MD, PhD.


Treatment guidelines modern oncology has improved oncological outcomes of cancer patients, but intrinsic and acquired drug resistance and relapse rates remain disappointingly high [1,2].  Future estimates suggest increase on incidence, late diagnosis and mortality rates if current conventional research and clinical practice will be continued [3].replica watches Recent whole genome and transcriptome next generation sequencing of bulk samples as well as single cell genomics and transcriptomics have unraveled extensive intratumor heterogeneity and discovery of multiple drug targets. Tumor region-to-region and cell-to-cell heterogeneity-guided drug sensitivity as well as complex cancer-immune cell interactions shape the new era of precision oncology [4-6]. In this focus article clinical predictive biomarkers to guide tailored multi-drug therapy is discussed. [7-9]. Moreover, combination drug therapy including molecularly targeted drugs and immunotherapeutic agents such as Pembrolizumab, Nivolumab, ipilimumab and atezolizumab as well as nine approved immune checkpoint inhibitors for tailored treatment on the basis of tumor mutational burden, PLD1, MMR/MSI guide precision immune-oncology in the clinical setting [10].

(Citation: Gastric & Breast Cancer 2021; 16(1): 64-71)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 1 January 2021